Sign inCreate account

Report workspace tools

NCT03839459COMPLETEDanonymous

Denosumab for Smoldering Multiple Myeloma

Sponsor

Source record

University of Rochester

Phase

Source record

PHASE2

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Denosumab

Indication / condition

AI-normalized

Smoldering Multiple Myeloma

Intervention

Source record

Denosumab

Source & freshness

Source record

NCT ID

NCT03839459

Original source

ClinicalTrials.gov

Source last updated

Jan 28, 2026

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03839459

Title

Denosumab for Smoldering Multiple Myeloma

Sponsor

University of Rochester

Status

COMPLETED

Phase

PHASE2

Condition raw

Smoldering Multiple Myeloma

Condition normalized

Smoldering Multiple Myeloma

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

Denosumab

Target normalized

Denosumab

Interventions

Denosumab

Public preview

Source record

This study will assess the safety and tolerability of denosumab in smoldering multiple myeloma subjects as well to see if denosumab can reduce subjects' risk of getting multiple myeloma.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Denosumab for Smoldering Multiple Myeloma

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03839459

Status

COMPLETED

Phase

PHASE2

Sponsor

University of Rochester

Executive brief

Investment-Ready Snapshot

This study will assess the safety and tolerability of denosumab in smoldering multiple myeloma subjects as well to see if denosumab can reduce subjects' risk of getting multiple myeloma.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 28, 2026
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03839459

Indication

Smoldering Multiple Myeloma

Modality

monoclonal antibody

Target

Denosumab

Intervention

Denosumab

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.